Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease

Authors Mohammed Al-Omran

Published 15 January 2008 Volume 2007:3(6) Pages 1019—1027

Mohammed Al-Omran

Department of Surgery, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Background: Peripheral arterial disease (PAD) is a marker of advanced atherosclerosis with an elevated risk of cardiovascular mortality and morbidity. Although intensive risk reduction therapy is critical in reducing the adverse cardiovascular outcomes in patients with PAD, the awareness of this information among all physicians is felt to be low. Given the role of family physicians (FP), general internists (GI), cardiologists (C), and vascular surgeons (VS) in treating patients with PAD, we sought to determine their perceptions and knowledge of risk reduction therapy in these patients.

Methods and results: We conducted a cross-sectional self-administered survey of 84 physicians who work at a major teaching hospital. FP, GI, C, and VS represent 39%, 33%, 16%, and 12% of the surveyed physicians, respectively. The recommended targets of LDL-cholesterol, blood glucose and blood pressure in PAD patients were known to 37.3%, 94.1% and 35.3% of physicians, respectively. The majority of physicians reported to screen for risk factors in PAD. Although 86.3% of physicians would recommend antiplatelets therapy in PAD, only 17.6% would recommend angiotensin converting enzyme (ACE) inhibitors; 25.5% would recommend nicotine replacement therapy for smokers and 62.7% would recommend statins. Compared to other specialties, cardiologists had the lowest threshold, whereas GI had the highest threshold for initiating antiplatelets and statins for patients with PAD.

Conclusion: The perceptions towards risk reduction in PAD identify glaring knowledge and action gaps. Effective strategies to encourage health professionals to use risk reduction therapy are needed.
Keywords: peripheral arterial disease, risk reduction, atherosclerosis

Download Article [PDF] 

Readers of this article also read:

Altered diastolic function and aortic stiffness in Alzheimer’s disease

Çalık AN, Özcan KS, Yüksel G, Güngör B, Aruğarslan E, Varlibas F, Ekmekci A, Osmonov D, Tatlısu MA, Karaca M, Bolca O, Erdinler I

Clinical Interventions in Aging 2014, 9:1115-1121

Published Date: 16 July 2014

Level of agreement between self-rated and clinician-rated instruments when measuring major depressive disorder in the Thai elderly: a 1-year assessment as part of the THAISAD study

Wongpakaran N, Wongpakaran T, Wannarit K, Saisavoey N, Pinyopornpanish M, Lueboonthavatchai P, Apisiridej N, Srichan T, Ruktrakul R, Satthapisit S, Nakawiro D, Hiranyatheb T, Temboonkiat A, Tubtimtong N, Rakkhajeekul S, Wongtanoi B, Tanchakvaranont S, Bookkamana P, Srisutasanavong U, Nivataphand R, Petchsuwan D

Clinical Interventions in Aging 2014, 9:377-382

Published Date: 25 February 2014


Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:3069-3070

Published Date: 20 June 2012

Bone integration capability of nanopolymorphic crystalline hydroxyapatite coated on titanium implants

Yamada M, Ueno T, Tsukimura N, Ikeda T, Nakagawa K, Hori N, Suzuki T, Ogawa T

International Journal of Nanomedicine 2012, 7:859-873

Published Date: 17 February 2012

Polyanionic carbohydrate doxorubicin–dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations

Yousefpour P, Atyabi F, Vasheghani Farahani E, Sakhtianchi R, Dinarvand R

International Journal of Nanomedicine 2011, 6:1487-1496

Published Date: 11 July 2011

Ankle Brachial Pressure Index (ABPI): An update for practitioners

Mo Al-Qaisi, David M Nott, David H King, et al

Vascular Health and Risk Management 2009, 5:833-841

Published Date: 30 September 2009

Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden

Anders Bergström, Frédérique Maurel, Claude Le Pen, et al

Clinical Ophthalmology 2009, 3:471-481

Published Date: 16 August 2009

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis

Noll Campbell, Amir Ayub, Malaz A Boustani, Chris Fox, Martin Farlow, et al

Clinical Interventions in Aging 2008, 3:719-728

Published Date: 5 December 2008